Insilico Medicine and TaiGen Biotechnology announced a licensing agreement under which TaiGen has obtained exclusive rights in Greater China—including Mainland China, Hong Kong, Macau and Taiwan—to develop, commercialize and sublicense ISM4808, an AI-driven oral prolyl hydroxylase domain (PHD) inhibitor designed for the treatment of anemia associated with chronic kidney disease (CKD). The agreement positions a potential “best-in-class” candidate for a condition with significant unmet medical need.
ISM4808 was nominated in 2022 and received clinical trial authorization from China’s Centre for Drug Evaluation (CDE) in 2023. The compound targets the HIF-α pathway, a mechanism recognized with a Nobel Prize, to boost erythropoietin (EPO) production and enhance iron utilization—processes crucial for correcting anemia in CKD patients. Insilico used its proprietary Chemistry42 AI platform to design, synthesize and test the molecule in roughly 12 months prior to candidate nomination, illustrating the efficiency of AI-driven drug discovery.
Preclinical studies reported that ISM4808 showed promising in vitro and in vivo efficacy, favorable oral drug-like properties, and a safety profile with high tolerated doses and broad margins. Under the terms of the deal, Insilico will receive an upfront payment, development and sales-based milestone payments, and tiered royalties on net sales, with the total agreement value expected in the double-digit millions of dollars. TaiGen will leverage its regional development and commercialization experience to advance the program toward patients in the CKD anemia market.
This collaboration reflects growing industry interest in applying generative AI to identify and progress novel therapeutic candidates for complex diseases such as CKD-associated anemia.
